100.31  -0.15 (-0.15%)		11-02 16:00
Open: 100.41 High: 100.59 Volume: 931,762		Pre. Close: 100.46 Low: 100.31 Market Cap: 6,550(M)

Short term
Mid term
Targets	6-month :	117.48	1-year :	137.22
Resists	First :	100.58	Second :	117.48
Pivot price	100.09
Supports	First :	99.79	Second :	99.3
MAs	MA(5) :	100.28	MA(20) :	100.1
	MA(100) :	102.12	MA(250) :	85.53
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	85.9	D(3) :	78
RSI	RSI(14): 54.4
52-week	High :	111.86	Low :	50.15

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LNTH ] has closed below upper band by 17.2%. Bollinger Bands are 83% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	100.64 - 101.01	101.01 - 101.31
Low:	99.21 - 99.69	99.69 - 100.07
Close:	99.75 - 100.48	100.48 - 101.07

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Mon, 02 Nov 2026
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting - The Manila Times

Fri, 30 Oct 2026
Vanguard amends its Lantheus (LNTH) stake report, with sole voting power over 60,159 shares. - Stock Titan

Fri, 30 Oct 2026
Lantheus Holdings, Inc. (LNTH) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Wed, 28 Oct 2026
LNTH Q3'26 Earnings: EPS estimate is 1.26 USD - TradingView

Wed, 28 Oct 2026
Lantheus Holdings, Inc. (LNTH) Stock Forecasts - Yahoo Finance

Sun, 25 Oct 2026
Lantheus Holdings, Inc. Estimates – NASDAQ:LNTH - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	65 (M)
Shares Float	59 (M)
Held by Insiders	1.7 (%)
Held by Institutions	115.5 (%)
Shares Short	3,780 (K)
Shares Short P.Month	4,240 (K)

EPS	4.13
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	20.1
Profit Margin	17.6 %
Operating Margin	25.8 %
Return on Assets (ttm)	8.3 %
Return on Equity (ttm)	22.2 %
Qtrly Rev. Growth	2.7 %
Gross Profit (p.s.)	14.33
Sales Per Share	23.88
EBITDA (p.s.)	6
Qtrly Earnings Growth	-0.9 %
Operating Cash Flow	413 (M)
Levered Free Cash Flow	452 (M)

PE Ratio	24.3
PEG Ratio	0
Price to Book value	4.99
Price to Sales	4.2
Price to Cash Flow	15.87

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.